In the treatment of breast cancer, ovarian cancer, prostate and pancreatic cancer, gBRCAm plays a crucial role in predicting the benefit of poly (adenosine diphosphate [ADP]—ribose) polymerase (PARP) inhibitors (PARPis). This evidence concerns the gene PARP1 and familial pancreatic carcinoma.